PledPharma presents PledOx®’s global phase III program at ASCO
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
PledPharma AB (publ) announces that the company’s global phase III program, POLAR, will be presented at a poster session during the American Society of Clinical Oncology (ASCO Annual meeting) May 31-June 4 in Chicago.
ASCO is the most prominent global conference within the field of oncology.
The title of the presentation is: The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).
It will be presented by one of the Coordinating Investigators of the POLAR M study, Dr Maryam Lustberg, The Ohio State Comprehensive Cancer Center, Columbus, OH, USA and Dr Stefan Carlsson, Chief Medical Officer at PledPharma.
”We are proud to have been selected as one of the presenters at ASCO. I see presenting the study at the most prominent oncology conference as a confirmation of the interest in PledOx®’s potential and the unmet medical need in this patient population.” says Nicklas Westerholm, CEO, PledPharma AB.
Meeting information:
Abstract number: TPS3616
Poster Session: Gastrointestinal (Colorectal) Cancer, 6/3/2019, 8:00 AM-11:00 AM
Poster Board: 107b